• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    7/25/23 9:05:55 AM ET
    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARAV alert in real time by email

    Gainers

    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock moved upwards by 45.4% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $30.6 million.
    • Enzo Biochem (NYSE:ENZ) shares rose 16.91% to $1.59. The market value of their outstanding shares is at $79.0 million.
    • Aravive (NASDAQ:ARAV) shares moved upwards by 14.09% to $1.7. The market value of their outstanding shares is at $101.7 million.
    • Novan (NASDAQ:NOVN) stock increased by 11.5% to $0.14. The market value of their outstanding shares is at $3.9 million.
    • Biotricity (NASDAQ:BTCY) stock rose 10.72% to $3.51. The market value of their outstanding shares is at $30.7 million.
    • Alpha Tau Medical (NASDAQ:DRTS) stock moved upwards by 9.97% to $4.41. The market value of their outstanding shares is at $305.5 million.

    Losers

    • Humanigen (NASDAQ:HGEN) shares decreased by 70.6% to $0.06 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.6 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) shares declined by 38.35% to $0.98. The company's market cap stands at $17.2 million.
    • Bellerophon Therapeutics (NASDAQ:BLPH) stock fell 34.27% to $0.47. The market value of their outstanding shares is at $4.8 million.
    • Stoke Therapeutics (NASDAQ:STOK) stock declined by 29.18% to $6.75. The company's market cap stands at $298.2 million.
    • Bionomics (NASDAQ:BNOX) stock decreased by 16.13% to $2.15. The company's market cap stands at $17.5 million.
    • ViewRay (NASDAQ:VRAY) shares fell 12.5% to $0.04. The company's market cap stands at $6.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARAV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAV
    $BFRG
    $BLPH
    $BNOX

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/24/2026$40.00Outperform
    Wolfe Research
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    NeuroOne Medical Technologies Corporation
    $NMTC
    5/5/2025$1.45Buy
    Ladenburg Thalmann
    Stoke Therapeutics Inc.
    $STOK
    12/20/2024$24.00Buy
    Chardan Capital Markets
    Stoke Therapeutics Inc.
    $STOK
    10/14/2024$18.00Outperform
    Leerink Partners
    Stoke Therapeutics Inc.
    $STOK
    3/26/2024Market Perform → Outperform
    TD Cowen
    More analyst ratings

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Mertens Steve covered exercise/tax liability with 7,376 shares, decreasing direct ownership by 5% to 153,047 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:27:42 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Business Development Director Christianson Mark covered exercise/tax liability with 1,812 shares, decreasing direct ownership by 0.79% to 228,920 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:20:36 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A covered exercise/tax liability with 71,325 shares, decreasing direct ownership by 6% to 1,082,590 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    2/20/26 2:15:19 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    SEC Filings

    View All

    SEC Form PRE 14A filed by NeuroOne Medical Technologies Corporation

    PRE 14A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    2/27/26 4:31:17 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Alpha Tau Medical Ltd.

    144 - Alpha Tau Medical Ltd. (0001871321) (Subject)

    2/26/26 7:28:14 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    NeuroOne Medical Technologies Corporation filed SEC Form 8-K: Other Events

    8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)

    2/25/26 4:30:28 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Stoke Therapeutics with a new price target

    Wolfe Research initiated coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $40.00

    2/24/26 7:56:29 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therapeu

    2/24/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

    - Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that Japan's Ministry of Health, Labour and Welfare ("MHLW") has granted regulatory (Shonin) marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally

    2/24/26 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on February 17, 2026, it granted stock options to purchase an aggregate of 22,950 shares of common stock to five new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $31.09 per share, which is equal to the closing price of

    2/18/26 4:01:00 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mcclurg Ronald W. bought $100,000 worth of shares (200,000 units at $0.50), increasing direct ownership by 82% to 444,117 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:47:21 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    CEO and President Rosa David A bought $50,000 worth of shares (100,000 units at $0.50), increasing direct ownership by 9% to 1,161,289 units (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    4/7/25 4:38:47 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Volker Christopher bought $105,000 worth of shares (75,000 units at $1.40) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    12/26/23 4:08:51 PM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Financials

    Live finance-specific insights

    View All

    Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA

    REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

    2/11/26 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th

    Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity's Founder and CEO, Dr. Waqa

    2/5/26 4:15:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

    REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter

    11/14/25 4:00:00 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Leadership Updates

    Live Leadership Updates

    View All

    NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

    EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary. Dave Rosa, President and CEO of NeuroOne said, "We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business.

    6/3/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

    JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., ("Oramed"), has been appointed to the Company's Board of Directors ("Board"). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. "Nadav is a fantastic addition to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "He has spent many years in a position much like ours, at the helm of a public compa

    5/12/25 4:01:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical Advisor

    Significant Neurological Expertise to Help Drive Clinical Development Strategy and Growth with New Technologies EDEN PRAIRIE, Minn., May 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has appointed Parag G. Patil, M.D., Ph.D., as Chief Medical Advisor (CMA), after serving on the company's Scientific Advisory Board since 2018. Dr. Parag G. Patil is a neurosurgeon-engineer with 20 years' experience serving patients and advancing innovative therapies to alleviate neurol

    5/12/25 8:30:00 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ARAV
    $BFRG
    $BLPH
    $BNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biotricity Inc.

    SC 13G/A - BIOTRICITY INC. (0001630113) (Subject)

    11/14/24 6:06:28 PM ET
    $BTCY
    Medical/Dental Instruments
    Health Care